Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Ultragenyx Pharmaceutical Inc. (RARE) is a Biotechnology company based in US with a market capitalization of $2.4B. Revenue grew 20.1% year-over-year and free cash flow was negative at -$472M. This page tracks RARE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 1.29K employees · IPO Jan 31, 2014
Valuation
Valuation & price
$25.00as of May 17, 2026· -39.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$2.4B
Market cap
20.1%
Revenue growth (YoY)
83.8%
Gross margin
-$472M
Free cash flow (USD)
$583M
Net debt
8.9%
Share dilution
1/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
6
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 6, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJun 15, 2026Filing
Insider Sell $47KParschauer Karah Herdman · EVP and Chief Legal Officer · $46.8K
- Insider sellJun 15, 2026Filing
Insider Sell $50KSanders Corazon (Corsee) D. · Director · $50.1K
- Insider sellJun 1, 2026Filing
Insider Sell $111KHorn Howard · Chief Financial Officer · $110.6K
- Insider sellMay 18, 2026Filing
Insider Sell $144KSULIMAN SHEHNAAZ · Director · $144.2K
- 8-K eventMay 18, 2026Filing
Incentive Plan Amended
- Insider sellMay 6, 2026Filing
Insider Sell $9KCrombez Eric · EVP and Chief Medical Officer · $8.6K
- Quarterly reportMay 6, 2026Filing
10-Q Filed
- 8-K eventMay 5, 2026Filing
Earnings Release
- Insider sellMay 4, 2026Filing
Insider Sell $117KHorn Howard · Chief Financial Officer · $116.6K
- Insider sellApr 2, 2026Filing
Insider Sell $98KHorn Howard · Chief Financial Officer · $98.2K
Questions
Frequently asked questions
What is Ultragenyx Pharmaceutical Inc.'s market cap?
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $2.4B.
What is RARE's P/E ratio?
A meaningful P/E ratio is not available for RARE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying RARE stock?
SEC Form 4 filings show no open-market insider buys at Ultragenyx Pharmaceutical Inc. in the last 90 days (6 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.